Loading...
Market
Primary beneficiary of DEA's telehealth prescribing rules by Dec 31, 2025?
2
Resolution / Starting Odds
Patients • 25%
Telehealth providers • 25%
Pharmaceutical companies • 25%
Other • 25%
Reports and analyses from healthcare industry publications
Story
DEA Extends Telehealth Prescribing for Opioid Addiction, ADHD Through December 31, 2025
Nov 18, 2024, 07:53 PM
Federal officials have announced a one-year extension of telehealth prescribing for controlled substances, including drugs for opioid addiction and ADHD, allowing health providers to continue offering these services through December 31, 2025. This decision marks the third extension of COVID-era telemedicine prescribing flexibilities, resolving a prolonged stalemate among policymakers. The Drug Enforcement Administration (DEA) confirmed the extension, which is expected to benefit both patients and telehealth providers, as it maintains access to necessary medications remotely. The announcement comes amid ongoing discussions about the future of telehealth regulations, with final rules anticipated from the incoming administration.
View original story
Similar markets
Addiction treatment • 25%
ADHD medication • 25%
Opioid prescriptions • 25%
Other controlled substances • 25%
Lobbying • 25%
Legal action • 25%
Public campaigns • 25%
No significant action • 25%
Growth • 25%
Decline • 25%
Stagnation • 25%
Diversification • 25%
Healthcare industry • 25%
Pharmaceutical companies • 25%
Public health advocacy groups • 25%
Government agencies • 25%
Extend waiver • 25%
End waiver • 25%
Modify waiver • 25%
No decision • 25%
Trump Administration • 33%
Next Administration • 33%
No permanent policy by end of 2025 • 34%
Yes • 50%
No • 50%